ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Bremelanotide (Vyleesi) for Female Sexual Disorder
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 147574" data-attributes="member: 3"><p>Bremelanotide, an investigational product candidate, is being developed for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women. The PDUFA date for bremelanotide is<strong> June 23, 2019</strong>. Bremelanotide is designed to be used in anticipation of a sexual encounter, and is thought to possess a novel mechanism of action that impacts the excitatory neural pathways in the brain to restore sexual desire.</p><p></p><p>Bremelanotide has been studied in more than 30 clinical trials with over 2,500 women. AMAG’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) was supported by clinical data from two identical large double-blind placebo-controlled Phase 3 studies in which bremelanotide met the pre-specified co-primary efficacy endpoints of improvement in desire and decrease in distress associated with low sexual desire as measured by validated patient-reported outcomes. Women in the trials had the option, after completion of the trial, to continue in an open-label safety extension study for an additional 12 months. Nearly 80% of patients elected to remain in the open-label portion of the study, and all of these patients received bremelanotide.</p><p></p><p>The most common adverse events were nausea, flushing, injection site reactions and headache. The majority of events were reported to be transient and mild-to-moderate in intensity.</p><p></p><p><a href="https://www.amagpharma.com/news/amag-pharmaceuticals-presents-new-data-at-the-american-college-of-obstetricians-and-gynecologists-annual-meeting/" target="_blank">AMAG PHARMACEUTICALS PRESENTS NEW DATA AT THE AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS ANNUAL MEETING – AMAG Pharmaceuticals</a></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 147574, member: 3"] Bremelanotide, an investigational product candidate, is being developed for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women. The PDUFA date for bremelanotide is[B] June 23, 2019[/B]. Bremelanotide is designed to be used in anticipation of a sexual encounter, and is thought to possess a novel mechanism of action that impacts the excitatory neural pathways in the brain to restore sexual desire. Bremelanotide has been studied in more than 30 clinical trials with over 2,500 women. AMAG’s New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) was supported by clinical data from two identical large double-blind placebo-controlled Phase 3 studies in which bremelanotide met the pre-specified co-primary efficacy endpoints of improvement in desire and decrease in distress associated with low sexual desire as measured by validated patient-reported outcomes. Women in the trials had the option, after completion of the trial, to continue in an open-label safety extension study for an additional 12 months. Nearly 80% of patients elected to remain in the open-label portion of the study, and all of these patients received bremelanotide. The most common adverse events were nausea, flushing, injection site reactions and headache. The majority of events were reported to be transient and mild-to-moderate in intensity. [URL="https://www.amagpharma.com/news/amag-pharmaceuticals-presents-new-data-at-the-american-college-of-obstetricians-and-gynecologists-annual-meeting/"]AMAG PHARMACEUTICALS PRESENTS NEW DATA AT THE AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS ANNUAL MEETING – AMAG Pharmaceuticals[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Bremelanotide (Vyleesi) for Female Sexual Disorder
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top